The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Bezuclastinib is COGT’s main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT’s SUMMIT ... on overexpressed HER2 or genetic mutations related to H1047R and KRAS.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of ...

GSK said that IDRX-42 addresses all the key KIT mutations that drive tumour growth and progression in GIST, which is estimated to affect between 4,000 and 6,000 people in the US each year.

The first 2 criteria are associated with imatinib's efficacy in CML (BCR-ABL fusion), GIST (KIT or PDGFRA mutation), and HES (FIP1L1-PDGFRA fusion). The information we have for SCLC in regard to ...

GIST typically presents in the GI tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation, and survival of tumor cells (primary or activating mutations).

Approximately 80% of all GIST cases are driven by mutations in the KIT gene. The US Senate today confirmed Robert F Kennedy Jr as Health and Human Services Secretary, after a vote that largely ...

The company's lead candidate is a selective tyrosine kinase inhibitor designed to target mutations within the KIT ... Gastrointestinal Stromal Tumors or GIST. Top-line from this trial 'PEAK ...

IDRx’s key pipeline candidate is IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI), which has shown the potential to address all key KIT mutations in GIST that drive tumor growth.